Mobile Menu - OpenMobile Menu - Closed

Hearing on "Combatting an Epidemic: Legislation to Help Patients with Substance Use Disorders"

Date: 
Tuesday, March 3, 2020 - 10:00am
Location: 
2123 Rayburn House Office Building
Subcommittees: 

The Subcommittee on Health of the Committee on Energy and Commerce held a legislative hearing on Tuesday, March 3, 2020, in the John D. Dingell Room, 2123 of the Rayburn House Office Building.  The hearing is entitled, "Combatting an Epidemic: Legislation to Help Patients with Substance Use Disorders."

 

Key Documents

Memorandum from Chairman Pallone to the Subcommittee on Health

Opening Statement of Chairman Pallone as prepared for delivery

Opening Statement of Subcommittee Chairwoman Eshoo as prepared for delivery

 

Livestream

 

Legislation

H.R. 1329, the "Medicaid Reentry Act"

H.R. 2281, the "Easy MAT for Opioid Addiction Act"

H.R. 2466, the "State Opioid Response Grant Authorization Act"

H.R. 2482, the "Mainstreaming Addiction Treatment Act of 2019"

H.R. 2922, the "Respond to the Needs in the Opioid War Act" or the "Respond NOW Act"

H.R. 3414, the "Opioid Workforce Act of 2019"

H.R. 3878, the "Block, Report, And Suspend Suspicious Shipments Act of 2019"

H.R. 4141, the "Humane Correctional Health Care Act"

H.R. 4793, the "Budgeting for Opioid Addiction Treatment Act"

H.R. 4812, the "Ensuring Compliance Against Drug Diversion Act of 2019"

H.R. 4814, the "Suspicious Order Identifying Act of 2019"

H.R. 4974, the "Medication Access and Training Expanision Act of 2019" or the "MATE Act of 2019"

H.R. 5572, the "Family Support Services for Addiction Act of 2020"

H.R. 5631, the "Solutions Not Stigmas Act of 2019"

 

Witnesses

Panel I

ADM Brett P. Giroir, M.D.
Assistant Secretary for Health and
Senior Adviser to the Secretary on Opioid Policy
U. S. Department of Health and Human Services

Testimony

 

Kimberly Brandt
Principal Deputy Administrator for Policy & Operations
Centers for Medicare & Medicaid Services

Testimony

 

Thomas W. Prevoznik
Deputy Assistant Administrator, Diversion Control Division
Drug Enforcement Administration

Testimony

 

Panel II

Michael P. Botticelli
Executive Director, Grayken Center for Addiction
Boston Medical Center

Testimony

 

Smita Das, MD, PhD, MPH
Addiction Psychiatrist, Dual Diagnosis Clinic
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
Stanford University School of Medicine

Testimony

 

Patty McCarthy
Chief Executive Officer
Faces & Voices of Recovery

Testimony

 

Robert I.L. Morrison
Executive Director/Director of Legislative Affairs
National Association of State Alcohol and Drug Abuse Directors

Testimony

 

Margaret B. Rizzo
Executive Director
JSAS HealthCare, Inc.

Testimony

 

Shawn A. Ryan, MD, MBA
Chair, Legislative Advocacy Committee
American Society of Addiction Medicine

Testimony

 

Issues: